Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas

Current Opinion in Neurology
Alberto PiccaMarc Sanson

Abstract

Hotspot mutations of isocitrate dehydrogenase 1 (R132) or 2 (R172) genes affect 40% of diffuse gliomas, mostly grades II and III. The mutant enzyme produces high quantities of d-2-hydroxyglutarate (D2HG), which reshapes the epigenetic of the cell leading to gliomagenesis. For the clinician, the isocitrate dehydrogenase (IDH) mutation is a major biomarker with diagnostic, prognostic, and predictive consequences. With the development of specific inhibitors and vaccination, it appears also a potential actionable target. IDH status is routinely determined on tumor sample by sequencing and immunohistochemistry detecting the most common mutant protein (IDH1R132H). Recently noninvasive diagnostic approaches have been developed based on the detection of the mutant DNA or the D2HG in body fluids, and the detection of D2HG by magnetic resonance spectroscopy of the brain. These new techniques open avenues for non invasive diagnostic of glioma in patients not amenable to biopsy, in the preoperative setting and also duringpatients follow-up for evaluation of treatment response and prediction of recurrence.

References

Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Feb 28, 2009·The American Journal of Pathology·Takuya WatanabeHiroko Ohgaki
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Oct 3, 2009·Acta Neuropathologica·David CapperAndreas von Deimling
Nov 17, 2009·Journal of Neuropathology and Experimental Neurology·Craig HorbinskiMarina N Nikiforova
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Apr 30, 2010·Neurology·M LabussièreM Sanson
Oct 5, 2010·Human Mutation·Blandine BoisselierMarc Sanson
Apr 5, 2011·EMBO Reports·Rasheduzzaman ChowdhuryAkane Kawamura
Sep 14, 2011·International Journal of Cancer. Journal International Du Cancer·David CapperUNKNOWN German Glioma Network
Oct 5, 2012·Neurology·Blandine BoisselierMarc Sanson
Mar 21, 2013·Acta Neuropathologica·Craig Horbinski
Dec 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maxime JaninStéphane de Botton
Jan 31, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Darrell R BorgerAndrew X Zhu
Feb 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Gregory CairncrossWalter J Curran
Jun 4, 2014·Acta Neuropathologica Communications·Aurélie CatteauCaterina Giannini
Jul 22, 2014·Nature·Theresa SchumacherMichael Platten
Apr 8, 2015·Acta Neuropathologica Communications·Serena PellegattaGaetano Finocchiaro
Jul 17, 2015·JAMA Oncology·Ganesh M ShankarMatthew Meyerson
Oct 21, 2015·Oncotarget·Jing WangZhong-Ping Chen
Nov 5, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ovidiu C AndronesiDaniel P Cahill
Dec 19, 2015·Cancer Cell·Kensuke TateishiDaniel P Cahill
Feb 3, 2016·The Oncologist·Amir T FathiAndrew S Chi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

© 2022 Meta ULC. All rights reserved